Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022) - By ALD Stages (Alcoholic Steatosis, Alcoholic Steatohepatitis), By NAFLD Stages (Steatosis, NASH)
Executive Summary
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Fatty Liver Disease Market on the basis of Type (Alcoholic Fatty Liver Disease or ALD), Non Alcoholic Fatty Liver Disease or NAFLD), By Alcoholic Fatty Liver Stages (Alcoholic Steatosis, Alcoholic Steatohepatitis), By Non Alcoholic Fatty Liver Stages (Non Alcoholic Steatosis, Non Alcoholic Steatohepatitis or NASH), By Alcoholic Liver Disease Drug (Opiod Antagonist, Glucocorticoid, Pentoxifyline, Antioxidants, Granulocyte colony stimulating factor), By Non Alcoholic Fatty Liver Drug (Antioxidants Thiazolidinedione, Biguanides, Lipid Lowering agents, FXR receptor agonist, Elafibranoer), By Region (North America, Europe, Asia Pacific and ROW) and By Country (U.S., Canada , U.K., France, Germany, China, Japan, India, Brazil, South Africa and Saudi Arabia).
Over the recent years, the global fatty liver disease incidence has been growing rapidly with increase in prevalence of obesity, type II diabetes along with rising consumption of alcohol. Globally, the growth in the fatty liver disease market is driven by rising awareness among people by government organizations and private companies, heavy investments by pharmaceutical companies for the development of drugs along with launch of drugs for NASH in the forecasted period.
According to Azoth Analytics research report, the report “Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022) - By ALD Stages (Alcoholic Steatosis ,Alcoholic Steatohepatitis), By NAFLD Stages (Steatosis, NASH)” analyses the Global Fatty Liver Disease Market, Analysis By Type (Alcoholic Fatty Liver Disease or ALD), Non Alcoholic Fatty Liver Disease or NAFLD), By Alcoholic Fatty Liver Stages (Alcoholic Steatosis, Alcoholic Steatohepatitis or ASH), By Non Alcoholic Fatty Liver Stages (Non Alcoholic Steatosis, Non Alcoholic Steatohepatitis or NASH), By Alcoholic Liver Disease Drug (Opiod Antagonist, Glucocorticoid, Pentoxifyline, Antioxidants, Granulocyte colony stimulating factor) and By Non Alcoholic Fatty Liver Drug (Antioxidants Thiazolidinedione, Biguanides, Lipid Lowering agents, FXR receptor agonist, Elafibranoer). The global market is projected to display a robust growth represented by a CAGR of 22.67% during 2017 – 2022, chiefly driven by rising prevalence of obesity, diabetes and hypertension, rising clinical trials in Asian countries, heavy investments by government of different countries in their health care sector, rising research in developing the different health care machines and methodology for the detection of alcohol and non-alcohol steatosis at its early stage.
The report titled, “Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022) - By ALD Stages (Alcoholic Steatosis ,Alcoholic Steatohepatitis), By NAFLD Stages (Steatosis, NASH)” has covered and analysed the potential of Global Fatty Liver Disease Market, NASH and NAFLD markets and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global fatty liver disease market. Additionally, the report also highlights market entry strategies for various companies across the globe.
Scope of the Report
Global Market (Actual Period: 2012-2016, Forecast Period: 2017-2022)
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Fatty Liver Disease Market on the basis of Type (Alcoholic Fatty Liver Disease or ALD), Non Alcoholic Fatty Liver Disease or NAFLD), By Alcoholic Fatty Liver Stages (Alcoholic Steatosis, Alcoholic Steatohepatitis), By Non Alcoholic Fatty Liver Stages (Non Alcoholic Steatosis, Non Alcoholic Steatohepatitis or NASH), By Alcoholic Liver Disease Drug (Opiod Antagonist, Glucocorticoid, Pentoxifyline, Antioxidants, Granulocyte colony stimulating factor), By Non Alcoholic Fatty Liver Drug (Antioxidants Thiazolidinedione, Biguanides, Lipid Lowering agents, FXR receptor agonist, Elafibranoer), By Region (North America, Europe, Asia Pacific and ROW) and By Country (U.S., Canada , U.K., France, Germany, China, Japan, India, Brazil, South Africa and Saudi Arabia).
Over the recent years, the global fatty liver disease incidence has been growing rapidly with increase in prevalence of obesity, type II diabetes along with rising consumption of alcohol. Globally, the growth in the fatty liver disease market is driven by rising awareness among people by government organizations and private companies, heavy investments by pharmaceutical companies for the development of drugs along with launch of drugs for NASH in the forecasted period.
According to Azoth Analytics research report, the report “Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022) - By ALD Stages (Alcoholic Steatosis ,Alcoholic Steatohepatitis), By NAFLD Stages (Steatosis, NASH)” analyses the Global Fatty Liver Disease Market, Analysis By Type (Alcoholic Fatty Liver Disease or ALD), Non Alcoholic Fatty Liver Disease or NAFLD), By Alcoholic Fatty Liver Stages (Alcoholic Steatosis, Alcoholic Steatohepatitis or ASH), By Non Alcoholic Fatty Liver Stages (Non Alcoholic Steatosis, Non Alcoholic Steatohepatitis or NASH), By Alcoholic Liver Disease Drug (Opiod Antagonist, Glucocorticoid, Pentoxifyline, Antioxidants, Granulocyte colony stimulating factor) and By Non Alcoholic Fatty Liver Drug (Antioxidants Thiazolidinedione, Biguanides, Lipid Lowering agents, FXR receptor agonist, Elafibranoer). The global market is projected to display a robust growth represented by a CAGR of 22.67% during 2017 – 2022, chiefly driven by rising prevalence of obesity, diabetes and hypertension, rising clinical trials in Asian countries, heavy investments by government of different countries in their health care sector, rising research in developing the different health care machines and methodology for the detection of alcohol and non-alcohol steatosis at its early stage.
The report titled, “Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022) - By ALD Stages (Alcoholic Steatosis ,Alcoholic Steatohepatitis), By NAFLD Stages (Steatosis, NASH)” has covered and analysed the potential of Global Fatty Liver Disease Market, NASH and NAFLD markets and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global fatty liver disease market. Additionally, the report also highlights market entry strategies for various companies across the globe.
Scope of the Report
Global Market (Actual Period: 2012-2016, Forecast Period: 2017-2022)
- Fatty Liver Disease market
- Breakdown –By NAFLD Stages (2012-2022): (Steatosis , NASH)
- Breakdown –By ALD Stages (2012-2022): (Steatosis, Alcohol Hepatitis)
- Breakdown by ALD Drugs (2012-2022): (Opioid Antagonist ,Glucocorticoid, Pentoxifyline, Antioxidants, Granulocyte colony stimulating factor)
- Breakdown By NAFLD Drug (2012-2022): (Antioxidants Thiazolidinedione, Biguanides, Hypolipidemic Agents, FXR receptor agonist, Elafibranoer)
- Fatty Liver Disease market
- Fatty Liver Disease market By Type (ALD, NAFLD)
- Breakdown by ALD Drugs (2012-2022)
- Breakdown By NAFLD Drug (2012-2022)
- Fatty Liver Disease market
- Fatty Liver Disease market By Type (ALD, NAFLD)
- Market Dynamics – Trends, Drivers, Challenges
- Policy and Regulation
- Company Analysis – Pfizer, Gilead Sciences ,Astra Zenca, Immuron, Novartis,Takeda, Allergan , Intercept Pharmaceuticals, Conatus
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
1. RESEARCH METHODOLOGY
2. EXECUTIVE SUMMARY
3. STRATEGIC RECOMMENDATION
3.1. Focus on Asia Region
3.2. Focus on drug development for NASH and Alcohol Hepatitis
3.3. Focus on early Stage detection of Alcohol and Non Alcoholic Steatosis
4. FATTY LIVER MARKET OUTLOOK
5. GLOBAL FATTY LIVER DISEASE MARKET: GROWTH AND FORECAST
5.1. By Value (2012-2016)
5.2. By Value (2017-2022)
6. GLOBAL FATTY LIVER DISEASE – ANALYSIS BY TYPE
6.1. Global Fatty Liver Disease Market -By Type (Alcoholic Fatty Liver Disease (ALD), Non Alcoholic Fatty Liver Disease (NAFLD)): Breakdown (%)
6.1.1. Global Fatty Liver Disease Market-By Type, 2016 (%)
6.1.2. Global Fatty Liver Disease Market-By Type, 2022 (%)
6.2. Global Fatty Liver Disease –By Type, By Value
6.2.1. Global Alcoholic Fatty Liver Disease Market
6.2.1.1. By Value (2012-2022)
6.2.2. Global Non Alcoholic Fatty Liver Disease Market
6.2.2.1. By Value (2012-2022)
7. GLOBAL ALCOHOLIC FATTY LIVER DISEASE MARKET – ANALYSIS BY STAGES
7.1. Global Alcoholic Fatty Liver Disease Market -By Stages (Alcoholic Steatosis and Alcoholic Steatohepatitis): Breakdown (%)
7.1.1. Global Alcoholic Fatty Liver Disease Market -By Stages, 2016 (%)
7.1.2. Global Alcoholic Fatty Liver Disease Market -By Stages, 2022 (%)
7.2. Global Alcoholic Fatty Liver Disease Market -By Stages, By Value
7.2.1. Global Alcoholic Steatosis Market
7.2.1.1. By Value (2012-2022)
7.2.2. Global Alcoholic Steatohepatitis Market
7.2.2.1. By Value (2012-2022)
8. GLOBAL NON ALCOHOLIC FATTY LIVER DISEASE MARKET– ANALYSIS BY STAGES
8.1. Global Non Alcoholic Fatty Liver Disease Market -By Stages (Non Alcoholic Steatosis and Non Alcoholic Steatohepatitis): Breakdown(%)
8.1.1. Global Non Alcoholic Fatty Liver Disease Market -By Stages, 2016 (%)
8.1.2. Global Non Alcoholic Fatty Liver Disease Market -By Stages, 2022 (%)
8.2. Global Non Alcoholic Fatty Liver Disease Market -By Stages , By Value
8.2.1. Global Non Alcoholic Steatosis Market
8.2.1.1. By Value (2012-2022)
8.2.2. Global Non Alcoholic Steatohepatitis Market
8.2.2.1. By Value (2012-2022)
9. GLOBAL ALCOHOLIC FATTY LIVER DISEASE MARKET – ANALYSIS BY DRUGS
9.1. Global Alcoholic Fatty Liver Disease Market -By Drugs (Opoid Antagonist, Glucocorticoid, Pentoxifyline, Antioxidants, Granulocyte colony stimulating factor): Breakdown (%)
9.1.1. Global Alcoholic Fatty Liver Disease Market -By Drugs, 2016 (%)
9.1.2. Global Non Alcoholic Fatty Liver Disease Market -By Drugs, 2022 (%)
9.2. Global Alcoholic Fatty Liver Disease Market - By Drugs , By Value
9.2.1. Global Opioid Antagonist Drug Market
9.2.1.1. By Value (2012-2022)
9.2.2. Global Pentoxifylline Drug Market
9.2.2.1.By Value (2012-2022)
9.2.3. Global Glucocorticoid Drug Market
9.2.3.1.By Value (2012-2022)
9.2.4. Global Antioxidants Drug market
9.2.4.1. By Value (2012-2022)
9.2.5. Global Granulocyte colony stimulating factor Drug Market
9.2.5.1. By Value (2012-2022)
10. GLOBAL NON ALCOHOLIC FATTY LIVER DISEASE MARKET –BY DRUGS
10.1. Global Non Alcoholic Fatty Live Disease Market -By Drugs (Antioxidants, Thiazolidinedione, Biguanides, Lipid Lowering Agents, FXR Receptor Agonist, Elafibranor): Breakdown (%)
10.1.1. Global Non Alcoholic Fatty Liver Disease Market -By Drugs, 2016 (%)
10.1.2. Global Non Alcoholic Fatty Liver Disease Market -By Drugs, 2022 (%)
10.2. Global Non Alcoholic Fatty Liver Disease Market -By Drugs , By Value
10.2.1. Global Antioxidants Drug Market
10.2.1.1. By Value (2012-2022)
10.2.2. Global Thiazolidinedione Drug Market
10.2.2.1.By Value (2012-2022)
10.2.3. Global Biguanides Drug Market
10.2.3.1. By Value (2012-2022)
10.2.4. Global Hypolipidemic Agents Drug market
10.2.4.1. By Value (2012-2022)
10.2.5. Global FXR Receptor Agonist Drug Market
10.2.5.1. By Value (2012-2022)
10.2.6. Global Elafibranor Drug Market
10.2.6.1. By Value (2012-2022)
11. GLOBAL FATTY LIVER DISEASE MARKET – PIPELINE ANALYSIS (BY DEVELOPER, PHASE AND INDICATION)
12. GLOBAL FATTY LIVER DISEASE MARKET – REGIONAL ANALYSIS
12.1. Global Fatty Liver Disease Market -By Regional: Breakdown (%)
12.1.1. Global Fatty Liver Disease Market -By Region, 2016(%)
12.1.2. Global Fatty Liver Disease Market -By Region, 2022 (%)
13. NORTH AMERICA FATTY LIVER DISEASE MARKET- AN ANALYSIS
13.1. By Value (2012-2022)
13.2. North America Fatty liver Disease Market – By Type , By Value
13.3. North America Fatty liver Disease Market – By ALD Drug, By Value
13.4. North America Fatty liver Disease Market – By NAFLD Drug , By Value
14. NORTH AMERICA FATTY LIVER DISEASE MARKET –BY COUNTRY ANALYSIS
14.1. North America Fatty Liver Disease Market –By Country, 2012-2016 (%)
14.2. North America Fatty Liver Disease Market –By Country, 2017E-2022F (%)
14.3. United States Fatty Liver Disease Market – By Value(2012-2022)
14.3.1. United States Fatty Liver Disease Market By Type, By Value
14.4. Canada Fatty Liver Disease Market – By Value(2012-2022)
14.4.1. Canada Fatty Liver Disease Market By Type, By Value
15. ASIA PACIFIC FATTY LIVER DISEASE MARKET - AN ANALYSIS
15.1. By Value (2012-2022)
15.2. Asia Pacific Fatty liver Disease Market – By Type, By Value
15.3. Asia Pacific Fatty liver Disease Market – By ALD Drug, By Value
15.4. Asia Pacific Fatty liver Disease Market – By NAFLD Drug, By Value
16. ASIA PACIFIC FATTY LIVER DISEASE MARKET – BY COUNTRY ANALYSIS
16.1. Asia Pacific Fatty Liver Disease Market –By Country, 2012-2016 (%)
16.2. Asia Pacific Fatty Liver Disease Market –By Country, 2017E-2022F (%)
16.3. India Fatty Liver Disease Market – By Value(2012-2022)
16.3.1. India Fatty Liver Disease Market By Type, By Value
16.4. China Fatty Liver Disease Market – By Value(2012-2022)
16.5. Japan Fatty Liver Disease Market – By Value(2012-2022)
16.5.1. Japan Fatty Liver Disease Market By Type, By Value
16.6. Rest of Asia Fatty Liver Disease Market-By Value(2012-2022)
17. EUROPE PACIFIC FATTY LIVER DISEASE MARKET- AN ANALYSIS
17.1. By Value (2012-2022)
17.2. Europe Fatty liver Disease Market – By Type, By Value
17.3. Europe Fatty liver Disease Market – By ALD Drug, By Value
17.4. Europe Fatty liver Disease Market – By NAFLD Drug, By Value
18. EUROPE FATTY LIVER DISEASE MARKET – BY COUNTRY ANALYSIS
18.1. Europe Fatty Liver Disease Market –By Country, 2012-2016 (%)
18.2. Europe Fatty Liver Disease Market –By Country, 2017E-2022F (%)
18.3. United Kingdom Fatty Liver Disease Market – By Value (2012-2022)
18.3.1. United Kingdom Fatty Liver Disease Market By Type, By Value
18.4. Germany Fatty Liver Disease Market – By Value(2012-2022)
18.4.1. Germany Fatty Liver Disease Market By Type, By Value
18.5. France Fatty Liver Disease Market – By Value(2012-2022)
18.5.1. France Fatty Liver Disease Market By Type, By Value
18.6. Rest of Europe Fatty Liver Disease Market-By Value (2012-2022)
19. REST OF WORLD FATTY LIVER DISEASE MARKET- AN ANALYSIS
19.1. By Value (2012-2022)
19.2. Rest of World Fatty liver Disease Market – By Type, By Value
19.3. Rest of World Fatty liver Disease Market – By ALD Drug, By Value
19.4. Rest of World Fatty liver Disease Market – By NAFLD Drug, By Value
20. REST OF WORLD FATTY LIVER DISEASE MARKET – BY COUNTRY ANALYSIS
20.1. Rest of World Fatty Liver Disease Market –By Country, 2012-2016 (%)
20.2. Rest of World Fatty Liver Disease Market –By Country, 2017E-2022F (%)
20.3. Saudi Arabia Fatty Liver Disease Market – By Value(2012-2022)
20.3.1. Saudi Arabia Fatty Liver Disease Market By Type, By Value
20.4. South Africa Fatty Liver Disease Market – By Value(2012-2022)
20.4.1. South Africa Fatty Liver Disease Market By Type, By Value
20.5. Brazil Fatty Liver Disease Market – By Value(2012-2022)
20.5.1. Brazil Fatty Liver Disease Market By Type, By Value
20.6. Others Fatty Liver Disease Market-By Value(2012-2022)
21. MARKET DYNAMICS
21.1. Drivers
21.2. Challenges
22. MARKET TRENDS
23. POLICY AND REGULATIONS
24. PORTER FIVE FORCE
25. SWOT ANALYSIS
26. COMPANY PROFILES
26.1. Pfizer
26.2. Conatus Pharmaceuticals
26.3. Novartis
26.4. Intercept Pharmaceuticals
26.5. Allergan
26.6. Immuron
26.7. Takeda
26.8. Gilead Sciences
26.9. Genfit
2. EXECUTIVE SUMMARY
3. STRATEGIC RECOMMENDATION
3.1. Focus on Asia Region
3.2. Focus on drug development for NASH and Alcohol Hepatitis
3.3. Focus on early Stage detection of Alcohol and Non Alcoholic Steatosis
4. FATTY LIVER MARKET OUTLOOK
5. GLOBAL FATTY LIVER DISEASE MARKET: GROWTH AND FORECAST
5.1. By Value (2012-2016)
5.2. By Value (2017-2022)
6. GLOBAL FATTY LIVER DISEASE – ANALYSIS BY TYPE
6.1. Global Fatty Liver Disease Market -By Type (Alcoholic Fatty Liver Disease (ALD), Non Alcoholic Fatty Liver Disease (NAFLD)): Breakdown (%)
6.1.1. Global Fatty Liver Disease Market-By Type, 2016 (%)
6.1.2. Global Fatty Liver Disease Market-By Type, 2022 (%)
6.2. Global Fatty Liver Disease –By Type, By Value
6.2.1. Global Alcoholic Fatty Liver Disease Market
6.2.1.1. By Value (2012-2022)
6.2.2. Global Non Alcoholic Fatty Liver Disease Market
6.2.2.1. By Value (2012-2022)
7. GLOBAL ALCOHOLIC FATTY LIVER DISEASE MARKET – ANALYSIS BY STAGES
7.1. Global Alcoholic Fatty Liver Disease Market -By Stages (Alcoholic Steatosis and Alcoholic Steatohepatitis): Breakdown (%)
7.1.1. Global Alcoholic Fatty Liver Disease Market -By Stages, 2016 (%)
7.1.2. Global Alcoholic Fatty Liver Disease Market -By Stages, 2022 (%)
7.2. Global Alcoholic Fatty Liver Disease Market -By Stages, By Value
7.2.1. Global Alcoholic Steatosis Market
7.2.1.1. By Value (2012-2022)
7.2.2. Global Alcoholic Steatohepatitis Market
7.2.2.1. By Value (2012-2022)
8. GLOBAL NON ALCOHOLIC FATTY LIVER DISEASE MARKET– ANALYSIS BY STAGES
8.1. Global Non Alcoholic Fatty Liver Disease Market -By Stages (Non Alcoholic Steatosis and Non Alcoholic Steatohepatitis): Breakdown(%)
8.1.1. Global Non Alcoholic Fatty Liver Disease Market -By Stages, 2016 (%)
8.1.2. Global Non Alcoholic Fatty Liver Disease Market -By Stages, 2022 (%)
8.2. Global Non Alcoholic Fatty Liver Disease Market -By Stages , By Value
8.2.1. Global Non Alcoholic Steatosis Market
8.2.1.1. By Value (2012-2022)
8.2.2. Global Non Alcoholic Steatohepatitis Market
8.2.2.1. By Value (2012-2022)
9. GLOBAL ALCOHOLIC FATTY LIVER DISEASE MARKET – ANALYSIS BY DRUGS
9.1. Global Alcoholic Fatty Liver Disease Market -By Drugs (Opoid Antagonist, Glucocorticoid, Pentoxifyline, Antioxidants, Granulocyte colony stimulating factor): Breakdown (%)
9.1.1. Global Alcoholic Fatty Liver Disease Market -By Drugs, 2016 (%)
9.1.2. Global Non Alcoholic Fatty Liver Disease Market -By Drugs, 2022 (%)
9.2. Global Alcoholic Fatty Liver Disease Market - By Drugs , By Value
9.2.1. Global Opioid Antagonist Drug Market
9.2.1.1. By Value (2012-2022)
9.2.2. Global Pentoxifylline Drug Market
9.2.2.1.By Value (2012-2022)
9.2.3. Global Glucocorticoid Drug Market
9.2.3.1.By Value (2012-2022)
9.2.4. Global Antioxidants Drug market
9.2.4.1. By Value (2012-2022)
9.2.5. Global Granulocyte colony stimulating factor Drug Market
9.2.5.1. By Value (2012-2022)
10. GLOBAL NON ALCOHOLIC FATTY LIVER DISEASE MARKET –BY DRUGS
10.1. Global Non Alcoholic Fatty Live Disease Market -By Drugs (Antioxidants, Thiazolidinedione, Biguanides, Lipid Lowering Agents, FXR Receptor Agonist, Elafibranor): Breakdown (%)
10.1.1. Global Non Alcoholic Fatty Liver Disease Market -By Drugs, 2016 (%)
10.1.2. Global Non Alcoholic Fatty Liver Disease Market -By Drugs, 2022 (%)
10.2. Global Non Alcoholic Fatty Liver Disease Market -By Drugs , By Value
10.2.1. Global Antioxidants Drug Market
10.2.1.1. By Value (2012-2022)
10.2.2. Global Thiazolidinedione Drug Market
10.2.2.1.By Value (2012-2022)
10.2.3. Global Biguanides Drug Market
10.2.3.1. By Value (2012-2022)
10.2.4. Global Hypolipidemic Agents Drug market
10.2.4.1. By Value (2012-2022)
10.2.5. Global FXR Receptor Agonist Drug Market
10.2.5.1. By Value (2012-2022)
10.2.6. Global Elafibranor Drug Market
10.2.6.1. By Value (2012-2022)
11. GLOBAL FATTY LIVER DISEASE MARKET – PIPELINE ANALYSIS (BY DEVELOPER, PHASE AND INDICATION)
12. GLOBAL FATTY LIVER DISEASE MARKET – REGIONAL ANALYSIS
12.1. Global Fatty Liver Disease Market -By Regional: Breakdown (%)
12.1.1. Global Fatty Liver Disease Market -By Region, 2016(%)
12.1.2. Global Fatty Liver Disease Market -By Region, 2022 (%)
13. NORTH AMERICA FATTY LIVER DISEASE MARKET- AN ANALYSIS
13.1. By Value (2012-2022)
13.2. North America Fatty liver Disease Market – By Type , By Value
13.3. North America Fatty liver Disease Market – By ALD Drug, By Value
13.4. North America Fatty liver Disease Market – By NAFLD Drug , By Value
14. NORTH AMERICA FATTY LIVER DISEASE MARKET –BY COUNTRY ANALYSIS
14.1. North America Fatty Liver Disease Market –By Country, 2012-2016 (%)
14.2. North America Fatty Liver Disease Market –By Country, 2017E-2022F (%)
14.3. United States Fatty Liver Disease Market – By Value(2012-2022)
14.3.1. United States Fatty Liver Disease Market By Type, By Value
14.4. Canada Fatty Liver Disease Market – By Value(2012-2022)
14.4.1. Canada Fatty Liver Disease Market By Type, By Value
15. ASIA PACIFIC FATTY LIVER DISEASE MARKET - AN ANALYSIS
15.1. By Value (2012-2022)
15.2. Asia Pacific Fatty liver Disease Market – By Type, By Value
15.3. Asia Pacific Fatty liver Disease Market – By ALD Drug, By Value
15.4. Asia Pacific Fatty liver Disease Market – By NAFLD Drug, By Value
16. ASIA PACIFIC FATTY LIVER DISEASE MARKET – BY COUNTRY ANALYSIS
16.1. Asia Pacific Fatty Liver Disease Market –By Country, 2012-2016 (%)
16.2. Asia Pacific Fatty Liver Disease Market –By Country, 2017E-2022F (%)
16.3. India Fatty Liver Disease Market – By Value(2012-2022)
16.3.1. India Fatty Liver Disease Market By Type, By Value
16.4. China Fatty Liver Disease Market – By Value(2012-2022)
16.5. Japan Fatty Liver Disease Market – By Value(2012-2022)
16.5.1. Japan Fatty Liver Disease Market By Type, By Value
16.6. Rest of Asia Fatty Liver Disease Market-By Value(2012-2022)
17. EUROPE PACIFIC FATTY LIVER DISEASE MARKET- AN ANALYSIS
17.1. By Value (2012-2022)
17.2. Europe Fatty liver Disease Market – By Type, By Value
17.3. Europe Fatty liver Disease Market – By ALD Drug, By Value
17.4. Europe Fatty liver Disease Market – By NAFLD Drug, By Value
18. EUROPE FATTY LIVER DISEASE MARKET – BY COUNTRY ANALYSIS
18.1. Europe Fatty Liver Disease Market –By Country, 2012-2016 (%)
18.2. Europe Fatty Liver Disease Market –By Country, 2017E-2022F (%)
18.3. United Kingdom Fatty Liver Disease Market – By Value (2012-2022)
18.3.1. United Kingdom Fatty Liver Disease Market By Type, By Value
18.4. Germany Fatty Liver Disease Market – By Value(2012-2022)
18.4.1. Germany Fatty Liver Disease Market By Type, By Value
18.5. France Fatty Liver Disease Market – By Value(2012-2022)
18.5.1. France Fatty Liver Disease Market By Type, By Value
18.6. Rest of Europe Fatty Liver Disease Market-By Value (2012-2022)
19. REST OF WORLD FATTY LIVER DISEASE MARKET- AN ANALYSIS
19.1. By Value (2012-2022)
19.2. Rest of World Fatty liver Disease Market – By Type, By Value
19.3. Rest of World Fatty liver Disease Market – By ALD Drug, By Value
19.4. Rest of World Fatty liver Disease Market – By NAFLD Drug, By Value
20. REST OF WORLD FATTY LIVER DISEASE MARKET – BY COUNTRY ANALYSIS
20.1. Rest of World Fatty Liver Disease Market –By Country, 2012-2016 (%)
20.2. Rest of World Fatty Liver Disease Market –By Country, 2017E-2022F (%)
20.3. Saudi Arabia Fatty Liver Disease Market – By Value(2012-2022)
20.3.1. Saudi Arabia Fatty Liver Disease Market By Type, By Value
20.4. South Africa Fatty Liver Disease Market – By Value(2012-2022)
20.4.1. South Africa Fatty Liver Disease Market By Type, By Value
20.5. Brazil Fatty Liver Disease Market – By Value(2012-2022)
20.5.1. Brazil Fatty Liver Disease Market By Type, By Value
20.6. Others Fatty Liver Disease Market-By Value(2012-2022)
21. MARKET DYNAMICS
21.1. Drivers
21.2. Challenges
22. MARKET TRENDS
23. POLICY AND REGULATIONS
24. PORTER FIVE FORCE
25. SWOT ANALYSIS
26. COMPANY PROFILES
26.1. Pfizer
26.2. Conatus Pharmaceuticals
26.3. Novartis
26.4. Intercept Pharmaceuticals
26.5. Allergan
26.6. Immuron
26.7. Takeda
26.8. Gilead Sciences
26.9. Genfit
LIST OF FIGURES
Figure 1: History of Fatty Liver Disease
Figure 2: Therapeutic Algorithm for Management of Alcoholic Hepatitis
Figure 3: Treatment Algorithm of NAFLD
Figure 4: Global Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Million)
Figure 5: Global Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Million)
Figure 6: Global Fatty Liver Disease Market Size, By Type, 2016 (%)
Figure 7: Global Fatty Liver Disease Market Size, By Type, 2022F (%)
Figure 8: Global Alcoholic Fatty liver Market Service Market, By Value, 2012-2016 (USD Billion)
Figure 9: Global Alcoholic Fatty liver Market Service Market, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 10: Beer Consumption, Billion Liters, 2014
Figure 11: Global Non Alcoholic Fatty Liver Disease Treatment Market, By Value, 2012-2016 (USD Billion)
Figure 12: Global Non Alcoholic Fatty Liver Disease Treatment Market, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 13: Global Diabetic Population, By Region, 2015 (Million)
Figure 14: Global Alcoholic Liver Disease Market Size, By Stage, 2016 (%)
Figure 15: Global Alcoholic liver Disease Market Size, By Type, 2022F (%)
Figure 16: Global Alcoholic Steatosis Treatment, By Value, 2012-2016 (USD Billion)
Figure 17: Global Alcoholic Steatosis Treatment, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 18: World Alcohol Consumption , Liters per Capita, 2014-2016
Figure 19: Global Alcoholic Staetohepatitis Market, By Value, 2012-2016 (USD Billion)
Figure 20: Global Alcoholic Staetohepatitis Market, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 21: Global Non Alcoholic Liver Disease Treatment Market Size, By Type, 2016 (%)
Figure 22: Global Non Alcoholic Liver Disease Treatment Market Size, By Type, 2022F (%)
Figure 23: Global Non Alcoholic Steatosis Treatment Market, By Value, 2012-2016 (USD Billion)
Figure 24: Global Non Alcoholic Steatosis Treatment Market, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 25: Global NASH Market, By Value, 2012-2016 (USD Billion)
Figure 26: Global NASH Market, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 27: Global Alcoholic Fatty Liver Market Size, By Drug, 2016 (%)
Figure 28: Global In-flight Catering Service Market Size, By Airline Type, 2022F (%)
Figure 29: Global Opioid Antagonist Drug Market, By Value, 2012-2016 (USD Billion)
Figure 30: Global Opioid Antagonist Drug Market, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 31: Global Pentoxifylline Drug Market, By Value, 2012-2016 (USD Billion)
Figure 32: Global Pentoxifylline Drug Market, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 33: Global Glucocoticoid Drug Market, By Value, 2012-2016 (USD Billion)
Figure 34: Global Glucocorticoid Drug Market, By ValueForecast, 2017E-2022F (USD Billion)
Figure 35: Global Antioxidants Drug Market, By Value, 2012-2016 (USD Billion)
Figure 36: Global Antioxidants Drug Market, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 37: Global Granulocyte Colony Stimulating Factor Drug Market, By Value, 2012-2016 (USD Billion)
Figure 38: Global Granulocyte Colony Stimulating Factor Drug Market, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 39: Global Non Alcoholic Fatty Liver Market Size, By Drug, 2016 (%)
Figure 40: Global Non Alcoholic Fatty Liver Market Size, By Drug, 2022F (%)
Figure 41: Global Antioxidants Drug Market, By Value, 2012-2016 (USD Billion)
Figure 42: Global Antioxidants Drug Market, By Value, Forecast, 2017E-2022 (USD Billion)
Figure 43: Global Thiazolidinedione Drug Market, By Value, 2012-2016 (USD Billion)
Figure 44: Global Thiazolidinedione Drug Market, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 45: Global Biguandies Drug Market, By Value, 2012-2016 (USD Billion)
Figure 46: Global Biguandies Drug Market, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 47: Global Hypolipidemic Drug Market, By Value, 2012-2016 (USD Billion)
Figure 48: Global Hypolipidemic Drug Market, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 49: Global FXR Receptor Agonist Drug Market, By Value, 2012-2016 (USD Billion)
Figure 50: Global FXR Receptor Agonist Drug Market, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 51: Global Elafibranor Drug Market, By Value, 2012-2016 (USD Billion)
Figure 52: Global Elafibranor Drug Market, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 53: Global Fatty Liver Disease Market Size and Share, By Region, 2016
Figure 54: Global Fatty Liver Disease Market Size and Share, By Segments, 2022F
Figure 55: North America Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)
Figure 56: North America Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 57: North America Healthcare Expenditure, 2011-2014 (% of GDP)
Figure 58: North America Population Age 15-64 2015 (% of Total)
Figure 59: North America Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
Figure 60: North America Fatty Liver Disease: By ALD Drug Type, By Value, 2012-2022 (USD Billion)
Figure 61: North America Fatty Liver Disease: By NAFLD Drug Type, By Value, 2012-2022 (USD Billion)
Figure 62: North America Fatty Liver Disease Market, Country Share, 2012-2016 (% of Total)
Figure 63: North America Fatty Liver Disease Market, Country Share, 2017-2022 (% of Total)
Figure 64: United States Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Figure 65: United States Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 66: Percentage of United states adults who had at least one heavy drinking day, 2011-2015
Figure 67: United States Alcohol Liters Per Capita Consumption, 2011-2015
Figure 68: United States Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
Figure 69: CanadaFatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Figure 70: Canada Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 71: Canada Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
Figure 72: Canada Alcohol Liters Per Capita Consumption, 2011-2015
Figure 73: Prevalence of Obese and overweight Population, By Age,2014(% )
Figure 74: Asia Pacific Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Figure 75: Asia PacificFatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 76: Obesity Prevalence in Asian Countries, 2014 (%)
Figure 77: Asia Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
Figure 78: Asia Fatty Liver Disease: By NAFLD Drug Type, By Value, 2012-2022 (USD Billion)
Figure 79: Asia Pacific Fatty Liver Disease: By ALD Drug Type, By Value, 2012-2022 (USD Billion)
Figure 80: Asia Pacific Fatty Liver Disease Market, Country Share, 2012-2016 (% of Total)
Figure 81: Asia Pacific Fatty Liver Disease Market, Country Share, 2017-2022 (% of Total)
Figure 82: India Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Figure 83: India Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 84: Percentage of United states adults who had at least one heavy drinking day, 2011-2015
Figure 85: India Alcohol Liter per capita Consumptions, 2015-2016
Figure 86: India Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
Figure 87: China Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)
Figure 88: China Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 89: Health expenditure in China, 2011-2015 (USD Billion)
Figure 90: China Alcohol Liter per capita Consumptions, 2015-2016
Figure 91: Japan Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)
Figure 92: Japan Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 93: Japan Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
Figure 94: Rest of Asia Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)
Figure 95: Rest of Asia Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 96: Europe Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)
Figure 97: Europe Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 98: Europe Diabetes Prevalence, By Country, 2015 (% of Population Aged 20 to 79)
Figure 99: EU Health Expenditure Per Capita, 2011-2014 (USD)
Figure 100: Breakdown of Total Health Expenditure in Europe (%)
Figure 101: Europe Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
Figure 102: Europe Fatty Liver Disease: By NAFLD Drug Type, By Value, 2012-2022 (USD Billion)
Figure 103: Europe Fatty Liver Disease: By ALD Drug Type, By Value, 2012-2022 (USD Billion)
Figure 104: Europe Fatty Liver Disease Market, Country Share, 2012-2016 (% of Total)
Figure 105: Europe Fatty Liver Disease Market, Country Share, 2017-2022 (% of Total)
Figure 106: United Kingdom Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Figure 107: United Kingdom Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 108: United Kingdom Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
Figure 109: Alcohol Related Disease Death, 2015
Figure 110: Diabetes Prevalence in U.K. 2015
Figure 111: Five Day Drinking Prevalence By Age, (%), 2014-2015
Figure 112: Germany Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Figure 113: Germany Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 114: Private Healthcare Spending in Germany, US Dollar/capita 2011 to 2015
Figure 115: Diabetes Prevalence in 55-74 age people in Germany, Forecast 2030F.
Figure 116: Alcohol Consumption per capita, 2012-2016 (liter) in Germany
Figure 117: Germany Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Million)
Figure 118: France Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Figure 119: France Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 120: France Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Million)
Figure 121: Rest Of Europe Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Figure 122: Rest of Europe Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 123: Rest of World Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)
Figure 124: Rest of World Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 125: Rest of World Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
Figure 126: Rest of World Fatty Liver Disease: By NAFLD Drug Type, By Value, 2012-2022 (USD Billion)
Figure 127: Rest of world Fatty Liver Disease: By ALD Drug Type, By Value, 2012-2022 (USD Billion)
Figure 128: Rest of World Fatty Liver Disease Market, Country Share, 2012-2016 (% of Total)
Figure 129: Rest of World Fatty Liver Disease Market, Country Share, 2017-2022 (% of Total)
Figure 130: Saudi Arabia Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Figure 131: Saudi Arabia Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 132: Saudi Arabia Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
Figure 133: Saudi Arabia Prevalence of Obesity Forecast 2022 (%)
Figure 134: South Africa Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Figure 135: South Africa Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 136: South Africa Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
Figure 137: Brazil Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Figure 138: Brazil Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 139: Brazil Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
Figure 140: Others Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)
Figure 141: Others Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 142: Pfizer Segmental Breakup, 2016 (%)
Figure 143: Pfizer Sales, By Region, 2016 (%)
Figure 144: Novartis Sales, By Segment 2015 (%)
Figure 145: Novartis Sales, By Region, 2015 (%)
Figure 146: Novartis Pharmaceuticals Sales, By Franchise, 2015 (%)
Figure 147: Takeda Segmental Breakup
Figure 148: Takeda Revenue, 2013-2016 (USD Million)
Figure 149: Gilead Sciences Product Sales, 2016 (%)
Figure 150: Gilead Sciences HCV Product Sales, 2014-2016 (USD Billion)
Figure 1: History of Fatty Liver Disease
Figure 2: Therapeutic Algorithm for Management of Alcoholic Hepatitis
Figure 3: Treatment Algorithm of NAFLD
Figure 4: Global Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Million)
Figure 5: Global Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Million)
Figure 6: Global Fatty Liver Disease Market Size, By Type, 2016 (%)
Figure 7: Global Fatty Liver Disease Market Size, By Type, 2022F (%)
Figure 8: Global Alcoholic Fatty liver Market Service Market, By Value, 2012-2016 (USD Billion)
Figure 9: Global Alcoholic Fatty liver Market Service Market, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 10: Beer Consumption, Billion Liters, 2014
Figure 11: Global Non Alcoholic Fatty Liver Disease Treatment Market, By Value, 2012-2016 (USD Billion)
Figure 12: Global Non Alcoholic Fatty Liver Disease Treatment Market, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 13: Global Diabetic Population, By Region, 2015 (Million)
Figure 14: Global Alcoholic Liver Disease Market Size, By Stage, 2016 (%)
Figure 15: Global Alcoholic liver Disease Market Size, By Type, 2022F (%)
Figure 16: Global Alcoholic Steatosis Treatment, By Value, 2012-2016 (USD Billion)
Figure 17: Global Alcoholic Steatosis Treatment, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 18: World Alcohol Consumption , Liters per Capita, 2014-2016
Figure 19: Global Alcoholic Staetohepatitis Market, By Value, 2012-2016 (USD Billion)
Figure 20: Global Alcoholic Staetohepatitis Market, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 21: Global Non Alcoholic Liver Disease Treatment Market Size, By Type, 2016 (%)
Figure 22: Global Non Alcoholic Liver Disease Treatment Market Size, By Type, 2022F (%)
Figure 23: Global Non Alcoholic Steatosis Treatment Market, By Value, 2012-2016 (USD Billion)
Figure 24: Global Non Alcoholic Steatosis Treatment Market, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 25: Global NASH Market, By Value, 2012-2016 (USD Billion)
Figure 26: Global NASH Market, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 27: Global Alcoholic Fatty Liver Market Size, By Drug, 2016 (%)
Figure 28: Global In-flight Catering Service Market Size, By Airline Type, 2022F (%)
Figure 29: Global Opioid Antagonist Drug Market, By Value, 2012-2016 (USD Billion)
Figure 30: Global Opioid Antagonist Drug Market, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 31: Global Pentoxifylline Drug Market, By Value, 2012-2016 (USD Billion)
Figure 32: Global Pentoxifylline Drug Market, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 33: Global Glucocoticoid Drug Market, By Value, 2012-2016 (USD Billion)
Figure 34: Global Glucocorticoid Drug Market, By ValueForecast, 2017E-2022F (USD Billion)
Figure 35: Global Antioxidants Drug Market, By Value, 2012-2016 (USD Billion)
Figure 36: Global Antioxidants Drug Market, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 37: Global Granulocyte Colony Stimulating Factor Drug Market, By Value, 2012-2016 (USD Billion)
Figure 38: Global Granulocyte Colony Stimulating Factor Drug Market, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 39: Global Non Alcoholic Fatty Liver Market Size, By Drug, 2016 (%)
Figure 40: Global Non Alcoholic Fatty Liver Market Size, By Drug, 2022F (%)
Figure 41: Global Antioxidants Drug Market, By Value, 2012-2016 (USD Billion)
Figure 42: Global Antioxidants Drug Market, By Value, Forecast, 2017E-2022 (USD Billion)
Figure 43: Global Thiazolidinedione Drug Market, By Value, 2012-2016 (USD Billion)
Figure 44: Global Thiazolidinedione Drug Market, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 45: Global Biguandies Drug Market, By Value, 2012-2016 (USD Billion)
Figure 46: Global Biguandies Drug Market, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 47: Global Hypolipidemic Drug Market, By Value, 2012-2016 (USD Billion)
Figure 48: Global Hypolipidemic Drug Market, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 49: Global FXR Receptor Agonist Drug Market, By Value, 2012-2016 (USD Billion)
Figure 50: Global FXR Receptor Agonist Drug Market, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 51: Global Elafibranor Drug Market, By Value, 2012-2016 (USD Billion)
Figure 52: Global Elafibranor Drug Market, By Value, Forecast, 2017E-2022F (USD Billion)
Figure 53: Global Fatty Liver Disease Market Size and Share, By Region, 2016
Figure 54: Global Fatty Liver Disease Market Size and Share, By Segments, 2022F
Figure 55: North America Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)
Figure 56: North America Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 57: North America Healthcare Expenditure, 2011-2014 (% of GDP)
Figure 58: North America Population Age 15-64 2015 (% of Total)
Figure 59: North America Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
Figure 60: North America Fatty Liver Disease: By ALD Drug Type, By Value, 2012-2022 (USD Billion)
Figure 61: North America Fatty Liver Disease: By NAFLD Drug Type, By Value, 2012-2022 (USD Billion)
Figure 62: North America Fatty Liver Disease Market, Country Share, 2012-2016 (% of Total)
Figure 63: North America Fatty Liver Disease Market, Country Share, 2017-2022 (% of Total)
Figure 64: United States Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Figure 65: United States Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 66: Percentage of United states adults who had at least one heavy drinking day, 2011-2015
Figure 67: United States Alcohol Liters Per Capita Consumption, 2011-2015
Figure 68: United States Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
Figure 69: CanadaFatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Figure 70: Canada Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 71: Canada Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
Figure 72: Canada Alcohol Liters Per Capita Consumption, 2011-2015
Figure 73: Prevalence of Obese and overweight Population, By Age,2014(% )
Figure 74: Asia Pacific Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Figure 75: Asia PacificFatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 76: Obesity Prevalence in Asian Countries, 2014 (%)
Figure 77: Asia Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
Figure 78: Asia Fatty Liver Disease: By NAFLD Drug Type, By Value, 2012-2022 (USD Billion)
Figure 79: Asia Pacific Fatty Liver Disease: By ALD Drug Type, By Value, 2012-2022 (USD Billion)
Figure 80: Asia Pacific Fatty Liver Disease Market, Country Share, 2012-2016 (% of Total)
Figure 81: Asia Pacific Fatty Liver Disease Market, Country Share, 2017-2022 (% of Total)
Figure 82: India Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Figure 83: India Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 84: Percentage of United states adults who had at least one heavy drinking day, 2011-2015
Figure 85: India Alcohol Liter per capita Consumptions, 2015-2016
Figure 86: India Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
Figure 87: China Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)
Figure 88: China Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 89: Health expenditure in China, 2011-2015 (USD Billion)
Figure 90: China Alcohol Liter per capita Consumptions, 2015-2016
Figure 91: Japan Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)
Figure 92: Japan Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 93: Japan Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
Figure 94: Rest of Asia Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)
Figure 95: Rest of Asia Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 96: Europe Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)
Figure 97: Europe Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 98: Europe Diabetes Prevalence, By Country, 2015 (% of Population Aged 20 to 79)
Figure 99: EU Health Expenditure Per Capita, 2011-2014 (USD)
Figure 100: Breakdown of Total Health Expenditure in Europe (%)
Figure 101: Europe Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
Figure 102: Europe Fatty Liver Disease: By NAFLD Drug Type, By Value, 2012-2022 (USD Billion)
Figure 103: Europe Fatty Liver Disease: By ALD Drug Type, By Value, 2012-2022 (USD Billion)
Figure 104: Europe Fatty Liver Disease Market, Country Share, 2012-2016 (% of Total)
Figure 105: Europe Fatty Liver Disease Market, Country Share, 2017-2022 (% of Total)
Figure 106: United Kingdom Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Figure 107: United Kingdom Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 108: United Kingdom Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
Figure 109: Alcohol Related Disease Death, 2015
Figure 110: Diabetes Prevalence in U.K. 2015
Figure 111: Five Day Drinking Prevalence By Age, (%), 2014-2015
Figure 112: Germany Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Figure 113: Germany Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 114: Private Healthcare Spending in Germany, US Dollar/capita 2011 to 2015
Figure 115: Diabetes Prevalence in 55-74 age people in Germany, Forecast 2030F.
Figure 116: Alcohol Consumption per capita, 2012-2016 (liter) in Germany
Figure 117: Germany Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Million)
Figure 118: France Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Figure 119: France Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 120: France Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Million)
Figure 121: Rest Of Europe Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Figure 122: Rest of Europe Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 123: Rest of World Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)
Figure 124: Rest of World Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 125: Rest of World Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
Figure 126: Rest of World Fatty Liver Disease: By NAFLD Drug Type, By Value, 2012-2022 (USD Billion)
Figure 127: Rest of world Fatty Liver Disease: By ALD Drug Type, By Value, 2012-2022 (USD Billion)
Figure 128: Rest of World Fatty Liver Disease Market, Country Share, 2012-2016 (% of Total)
Figure 129: Rest of World Fatty Liver Disease Market, Country Share, 2017-2022 (% of Total)
Figure 130: Saudi Arabia Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Figure 131: Saudi Arabia Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 132: Saudi Arabia Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
Figure 133: Saudi Arabia Prevalence of Obesity Forecast 2022 (%)
Figure 134: South Africa Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Figure 135: South Africa Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 136: South Africa Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
Figure 137: Brazil Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)
Figure 138: Brazil Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 139: Brazil Fatty Liver Disease: By Type, By Value, 2012-2022 (USD Billion)
Figure 140: Others Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)
Figure 141: Others Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)
Figure 142: Pfizer Segmental Breakup, 2016 (%)
Figure 143: Pfizer Sales, By Region, 2016 (%)
Figure 144: Novartis Sales, By Segment 2015 (%)
Figure 145: Novartis Sales, By Region, 2015 (%)
Figure 146: Novartis Pharmaceuticals Sales, By Franchise, 2015 (%)
Figure 147: Takeda Segmental Breakup
Figure 148: Takeda Revenue, 2013-2016 (USD Million)
Figure 149: Gilead Sciences Product Sales, 2016 (%)
Figure 150: Gilead Sciences HCV Product Sales, 2014-2016 (USD Billion)
LIST OF TABLES
Table A: Causes of NAFLD Infection
Table B: Quantity of Alcohol in Standard Drink
Table C: Alcoholic Fatty Liver Disease Market Analysis, By Drug, Developer, Phase, Indication
Table D: Non Alcoholic Fatty Liver Disease Market Analysis, By Drug, Developer, Phase, Indication
Table E: Non Alcoholic Fatty Liver Disease Market Analysis, By Drug, Developer, Phase, Indication
Table F: NASH Multi Therapy Treatment Market Analysis, By Drug, Developer, Phase, Indication, Status
Table A: Causes of NAFLD Infection
Table B: Quantity of Alcohol in Standard Drink
Table C: Alcoholic Fatty Liver Disease Market Analysis, By Drug, Developer, Phase, Indication
Table D: Non Alcoholic Fatty Liver Disease Market Analysis, By Drug, Developer, Phase, Indication
Table E: Non Alcoholic Fatty Liver Disease Market Analysis, By Drug, Developer, Phase, Indication
Table F: NASH Multi Therapy Treatment Market Analysis, By Drug, Developer, Phase, Indication, Status
